Dr. de Min brings over 25 years’ experience in drug development in both big pharma and biotech. She will drive the advancement of Topas’ development programs, including lead clinical program TPM203 for treatment of pemphigus vulgaris and TPM502 for treatment of celiac disease.
PRESS RELEASES & ARTICLES
STAY UPDATED
Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
January 13, 2022
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties. Advanz gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
January 12, 2022
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech. Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech, as well as research funding, and will be eligible to receive development, regulatory and commercial milestone payments up to a total of more than $750 million, plus tiered royalties on global net sales.
Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial
October 23, 2020
PDFTopas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
December 18, 2019
PDFCrescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
September 12, 2019
PDFImmatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
August 28, 2019
PDFImmatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
July 19, 2019
PDFImmatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
April 09, 2019
PDFImmatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
February 26, 2019
PDFUS Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
January 03, 2019
PDFNature publication reports first-in-human trial for a personalized cancer immunotherapy
December 20, 2018
PDFOpsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH)
October 25, 2018
PDFEMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction.
September 13, 2018
PDFTopas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
November 02, 2017
PDFImmatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
October 04, 2017
PDFCrescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards
June 16, 2017
PDF